Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 7/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 8/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.48 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.48 |
| ▸ | RAF1 | P04049 | 2/20 | 0.48 |
| ▸ | KDR | P35968 | 2/20 | 0.48 |
| ▸ | MAP2K2 | P36507 | 2/20 | 0.48 |
| ▸ | TGFBR2 | P37173 | 2/20 | 0.48 |
| ▸ | NEK2 | P51955 | 2/20 | 0.48 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.48 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.48 |
| ▸ | MAP2K5 | Q13163 | 2/20 | 0.48 |
| ▸ | PTK6 | Q13882 | 2/20 | 0.48 |
| ▸ | NEK11 | Q8NG66 | 2/20 | 0.48 |
| ▸ | MAP3K20 | Q9NYL2 | 2/20 | 0.48 |
| ▸ | MAP4K5 | Q9Y4K4 | 2/20 | 0.48 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.48 |
| ▸ | PLK4 | O00444 | 1/20 | 0.48 |
| ▸ | PIR | O00625 | 1/20 | 0.48 |
| ▸ | AURKA | O14965 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19068717 | 0.90 | BRAF (0.41) | BRAFCYP2C19CYP2C9RIPK2RAF1 | |
| SCHEMBL3505940 | 0.88 | CYP2C19 (0.52) | BRAFCYP2C19CYP2C9RIPK2RAF1 | |
| SCHEMBL13505690 | 0.88 | BRAF (0.52) | BRAFCYP2C19CYP2C9RIPK2RAF1 | |
| SCHEMBL30078249 | 0.87 | BRAF (0.62) | BRAFCYP2C19CYP2C9RIPK2RAF1 | |
| SCHEMBL298199 | 0.87 | BRAF (0.62) | BRAFCYP2C19CYP2C9RIPK2RAF1 | |
| SCHEMBL3703309 | 0.87 | BRAF (0.51) | BRAFCYP2C19CYP2C9RIPK2RAF1 | |
| SCHEMBL29482811 | 0.86 | BRAF (0.66) | BRAFCYP2C19CYP2C9RIPK2RAF1 | |
| SCHEMBL293715 | 0.86 | BRAF (0.64) | BRAFCYP2C19CYP2C9RIPK2RAF1 | |
| SCHEMBL2015374 | 0.86 | BRAF (0.66) | BRAFCYP2C19CYP2C9RIPK2RAF1 | |
| SCHEMBL12634001 | 0.84 | BRAF (0.50) | BRAFCYP2C19CYP2C9RIPK2RAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250195516-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2025-06-19 | — | — | US | disclosed |
| US-20230277534-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230277534-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230277534-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2023-09-07 | — | — | US | disclosed |
| US-11337976-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-11337976-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2022-05-24 | — | — | US | disclosed |
| CN-113893253-A | PLX-8394 or PLX-7904 for the treatment of BRAF-V600 related diseases | 普莱希科公司 | 2022-01-07 | — | — | CN | disclosed |
| EP-2672967-B1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2018-10-17 | — | — | EP | disclosed |
| EP-3297630-A1 | PLX-8394 OR PLX-7904 FOR USE IN THE TREATMENT OF BRAF-V600-RELATED DISEASES | PLEXXIKON INC. (US) | 2018-03-28 | — | — | EP | disclosed |
| US-9814714-B2 | Kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-20110183988-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2011-07-28 | — | — | US | disclosed |
| US-20110183988-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2011-07-28 | — | — | US | disclosed |
| WO-2011079133-A2 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. (US) | 2011-06-30 | — | — | WO | disclosed |
| WO-2011079133-A2 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. (US) | 2011-06-30 | — | — | WO | disclosed |
| WO-2010129570-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | PLEXXIKON, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
| WO-2010129570-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | PLEXXIKON, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
| WO-2010129567-A1 | PYRROLO [2, 3. B] PYRIDINES WHICH INHIBIT RAF PROTEIN KINASE | PLEXXIKON, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
| US-20100286142-A1 | Compounds and Methods for Kinase Modulation, and Indications Therefor | PLEXXIKON, INC. | 2010-11-11 | — | — | US | disclosed |
| US-20100286142-A1 | Compounds and Methods for Kinase Modulation, and Indications Therefor | PLEXXIKON, INC. | 2010-11-11 | — | — | US | disclosed |
| US-20100286142-A1 | Compounds and Methods for Kinase Modulation, and Indications Therefor | PLEXXIKON, INC. | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11337976-B2 | Compounds and methods for kinase modulation, and indications therefor | MAP3K20, PRKACA, MAP3K13 | BRAF 49/4885CYP2C19 4608/4885CYP2C9 4771/4885 |
| US-20230277534-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, PRKACA, MAP3K13 | BRAF 49/4885CYP2C19 4608/4885CYP2C9 4771/4885 |
| US-20100286142-A1 | Compounds and Methods for Kinase Modulation, and Indications Therefor | BRAF, ARAF, RAF1 | BRAF 1/4885CYP2C19 2678/4885CYP2C9 2237/4885 |
| US-20250195516-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | MAP3K20, PRKACA, MAP3K13 | BRAF 49/4885CYP2C19 4608/4885CYP2C9 4771/4885 |
| US-20110183988-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | BRAF, ARAF, NRAS | BRAF 1/4885CYP2C19 2453/4885CYP2C9 2483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.